HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Estazolam

HCID 3261
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
29975-16-4
Standard SMILES
Clc1ccc2c(c1)C(c1ccccc1)=NCc1nncn1-2
InChIKey
CDCHDCWJMGXXRH-UHFFFAOYSA-N
Molecular formula
C16H11ClN4
Average molar mass
294.74 g/mol
Monoisotopic mass
294.0672241

Overview

Estazolam is a triazolo[4,3-a][1,4]benzodiazepine having a phenyl group at position 6 and a chloro substituent at position 8. A short-acting benzodiazepine with general properties similar to diazepam, it is given by mouth as a hypnotic in the short-term management of insomnia. It has a role as an anxiolytic drug, an anticonvulsant and a GABA modulator. It is a triazolobenzodiazepine and a member of triazoles.

Names & identifiers

Preferred name
Estazolam
IUPAC
8-chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
English name
Estazolam
Molecular formula
C16H11ClN4
Molecular weight
294.74

Names & synonyms

estazolam29975-16-4EurodinProSomEsilganD 40TAEstazolamum8-Chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepineAbbott-47631Estazolam civDTXSID50205728-Chloro-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine
Show more names
8-CHLORO-6-PHENYL-4H-[1,2,4]-TRIAZOLO[4,3-A][1,4]BENZODIAZEPINEu33737Cannocd-40taNemurelJulodin
NSC-29081836S3EQV54C4H-(1,2,4)Triazolo(4,3-a)(1,4)benzodiazepine, 8-chloro-6-phenyl-8-Chloro-6-phenyl-4H-(1,2,4)triazolo-(4,3-a)(1,4)benzodiazepineDTXCID50572CHEBI:48588-Chloro-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepineNSC290818

Database identifiers

CAS
29975-16-4
PubChem CID
3261
DTXSID
DTXSID5020572
ChEMBL
CHEMBL285674
ChEBI
CHEBI:4858
UNII

Properties

Computed structural propertiesFilling in

XLogP
1.7
Topological polar surface area
43.1 Ų
Hydrogen bond donors
0
Hydrogen bond acceptors
3
Rotatable bonds
1
Heavy atoms
21
Formal charge
0
Complexity
407

Experimental & physicochemical properties

Drugs · 5 items

DEA NFLIS-Drug Category -> Benzodiazepines

DEA Schedule IV Controlled Substance -> Depressants

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Benzodiazepines

Pharmaceuticals -> Synthetic Cannabinoids or Psychoactive Compounds

LogP4.7
Solubility · 2 items

Practically insoluble (1.5 mg/L)

4.23e-02 g/L

Human Drugs · 4 items

Breast Feeding; Lactation; Milk, Human; Benzodiazepines; Hypnotics and Sedatives

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Pharmaceuticals

Melting Point · 2 items

228-229

228.5 °C

Physical DescriptionSolid
Collision Cross Section168.1 Ų [M+H]+ [CCS Type: DT; Method: single field calibrated]

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 5 items

This chemical does not meet GHS hazard criteria for 2.3% (1 of 44) of reports.

Warning

H315 (93.2%): Causes skin irritation [Warning Skin corrosion/irritation]

P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 44 reports by companies from 7 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Regulatory Information · 2 items

DEA schedule IV controlled substance

4H-1,2,4Triazolo4,3-a1,4benzodiazepine, 8-chloro-6-phenyl-: Does not have an individual approval but may be used under an appropriate group standard

Hazard Classes and CategoriesSkin Irrit. 2 (93.2%)

Toxicology

Treatment · 1 item

Gastric evacuation, either by the induction of emesis, lavage, or both, should be performed immediately. Maintenance of adequate ventilation is essential. General supportive care, including frequent monitoring of the vital signs and close observation of the patient, is indicated. Fluids should be administered intravenously to maintain blood pressure and encourage diuresis. The value of dialysis in treatment of benzodiazepine overdose has not been determined. The physician may wish to consider contacting a Poison Control Center for up-to-date information on the management of hypnotic drug product overdose. Flumazenil, a specific benzodiazepine receptor antagonist, is indicated for the complete or partial reversal of the sedative effects of benzodiazepines and may be used in situations when an overdose with a benzodiazepine is known or suspected. (L1712)

Chemistry & industry

Pharmacology

ATC Code · 2 items

N - Nervous system

QN - Nervous system

Protein Binding93% protein bound, independant of concentration.
PharmacodynamicsEstazolam, a triazolobenzodiazepine derivative, is an oral hypnotic agent with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam.
Mechanism of Action · 1 item

Benzodiazepines bind nonspecifically to benzodiazepine receptors, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABA<sub>A</sub>) receptors, this enhances the effects GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.

Biological Half-LifeThe range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.
Metabolism/Metabolites · 3 items

Extensively metabolized in the liver. In vitro studies with human liver microsomes indicate that the biotransformation of estazolam to the major circulating metabolite 4-hydroxy-estazolam is mediated by cytochrome P450 3A (CYP3A).

Estazolam has known human metabolites that include 4-hydroxyestazolam.

Extensively metabolized in the liver. In vitro studies with human liver microsomes indicate that the biotransformation of estazolam to the major circulating metabolite 4-hydroxy-estazolam is mediated by cytochrome P450 3A (CYP3A). Route of Elimination: Estazolam is extensively metabolized. The elimination of the parent drug takes place via hepatic metabolism of estazolam to hydroxylated and other metabolites that are eliminated largely in the urine both free and conjugated. Less than 5% of a 2 mg dose of estazolam was excreted unchanged in the urine, with only 4% of the dose appearing in the feces. Radiolabel mass balance studies indicate that the main route of excretion is via the kidneys. After 5 days, 87% of the administered radioactivity was excreted in human urine. Less than 4% of the dose was excreted unchanged. Half Life: The range of estimates for the mean elimination half-life of estazolam varies from 10 to 24 hours.

Related reactions

7 records
New reaction record
HRID 615852 reaction equation
HRID 615852As reactant
HRID 615853 reaction equation
HRID 615853As reactant
HRID 867066 reaction equation
HRID 867066As product
HRID 1288066 reaction equation
HRID 1288066As product
HRID 1764511 reaction equation
HRID 1764511As product
HRID 1764512 reaction equation
HRID 1764512As product
HRID 1764513 reaction equation
HRID 1764513As product

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
36S3EQV54C
EC Number
249-982-4
Nikkaji
J9.280K

Physicochemical properties

Melting point
228 · 228-229°
Boiling point
448.04 °C · 448.04°C (rough estimate)
Density
1.2294 · 1.2294 (rough estimate)
refractive index
1.611 · 1.6110 (estimate)
Flash point
11 °C · 11 °C
storage temp.
2 · 2-8°C
solubility
30 mg/ml; · DMF: 30 mg/ml; DMF:PBS(pH 7.2)(1:1): 0.5 mg/ml; DMSO: 20 mg/ml; Ethanol: 10 mg/ml
form
A crystalline solid
pka
2.84 · pKa 2.84(H2O) (Uncertain)
CAS DataBase Reference
29975 · 29975-16-4(CAS DataBase Reference)
EWG's Food Scores
1 · 1
FDA UNII
36 S3EQV54C · 36S3EQV54C
NIST Chemistry Reference
Estazolam(29975-16-4)
ATC code
5 CD04 · N05CD04
IARC
3 · 3 (Vol. 66) 1996
Symbol(GHS)
2 · GHS02,GHS06,GHS08
Signal word
Danger
Hazard statements
225 · H225-H301+H311+H331-H370
Precautionary statements
210 · P210-P260-P280-P301+P310-P311
Hazard Codes
Xi,T,F
Risk Statements
36 · 36/37/38-39/23/24/25-23/24/25-11
Safety Statements
36 · 36/37/39-45-36/37-16-7
RIDADR
3249 · 3249
WGK Germany
3 · 3
RTECS
5473500 · XZ5473500
HazardClass
6.1 · 6.1(b)
PackingGroup
III
HS Code
2933910000 · 2933910000
Toxicity
50 orally · LD50 orally in male mice, rats and rabbits: 740, 3200, 300 mg/kg (Yokotani)
Health EffectsMay cause a potentially dangerous rash that may develop into Stevens Johnson syndrome, an extremely rare but potentially fatal skin disease.
Hepatotoxicity · 1 item

Estazolam, as with other benzodiazepines, is rarely associated with serum ALT elevations, and clinically apparent liver injury from estazolam is extremely rare, if it occurs at all. There have been no published case reports of symptomatic, acute liver injury from estazolam. Isolated cases of clinically apparent hepatitis have been reported with other benzodiazepines including alprazolam, chlordiazepoxide, clonazepam, diazepam, flurazepam, lorazepam, and triazolam. The clinical pattern of acute liver injury from benzodiazepines is typically cholestatic and mild-to-moderate in severity with a latency of 1 to 6 months and full recovery within 1 to 2 months. Fever and rash have not been described nor has autoantibody formation.

Exposure Routes · 1 item

Tablets have been found to be equivalent in absorption to an orally administered solution of estazolam. In healthy subjects who received up to three times the recommended dose, peak estazolam plasma concentrations occurred within two hours after dosing (range 0.5 to 6.0 hours) and were proportional to the administered dose, suggesting linear pharmacokinetics over the dosage range tested.

Toxicity Summary · 1 item

Benzodiazepines bind nonspecifically to benzodiazepine receptors, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABA<sub>A</sub>) receptors, this enhances the effects GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.

Signs and SymptomsSymptoms of overdose include confusion, depressed breathing, drowsiness and eventually coma, lack of coordination, and slurred speech.
Carcinogen Classification · 6 items

Estazolam

Group 3: Not classifiable as to its carcinogenicity to humans

Volume 66: (1996) Some Pharmaceutical Drugs

1996

1996

3, not classifiable as to its carcinogenicity to humans. (L135)

Drug Induced Liver Injury · 6 items

Drug Induced Liver Injury Rank (DILIrank 2.0)

Estazolam

vNo-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation · 2 items

◉ Summary of Use during Lactation

◈ What is estazolam?

Toxicity DataLD50: 740 mg/kg (oral, male mice) (L1867) LD50: 3200 mg/kg (oral, rat) (L1867) LD50 300 mg/kg (oral, rabbit) (L1867)

Safety data

wgk
3
rtecs
XZ5473500
ridadr
3249
hs_code
2933910000
Toxicity
LD50 orally in male mice, rats and rabbits: 740, 3200, 300 mg/kg (Yokotani)
risk_code
36/37/38-39/23/24/25-23/24/25-11
Signal word
Danger
Symbol(GHS)
GHS02,GHS06,GHS08
hazard_code
Xi,T,F
safety_code
36/37/39-45-36/37-16-7
hazard_class
6.1(b)
packing_group
III
Hazard statements
H225-H301+H311+H331-H370
Precautionary statements
P210-P260-P280-P301+P310-P311
FDA Pharmacological Classification · 6 items

36S3EQV54C

ESTAZOLAM

Established Pharmacologic Class [EPC] - Benzodiazepine

Chemical Structure [CS] - Benzodiazepines

Estazolam is a Benzodiazepine.

ESTAZOLAM

MeSH Pharmacological Classification · 3 items

Drugs used to prevent SEIZURES or reduce their severity.

Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here.

Substances that do not act as agonists or antagonists but do affect the GAMMA-AMINOBUTYRIC ACID receptor-ionophore complex. GABA-A receptors (RECEPTORS, GABA-A) appear to have at least three allosteric sites at which modulators act: a site at which BENZODIAZEPINES act by increasing the opening frequency of GAMMA-AMINOBUTYRIC ACID-activated chloride channels; a site at which BARBITURATES act to prolong the duration of channel opening; and a site at which some steroids may act. GENERAL ANESTHETICS probably act at least partly by potentiating GABAergic responses, but they are not included here.

Absorption, Distribution and Excretion · 2 items

Tablets have been found to be equivalent in absorption to an orally administered solution of estazolam. In healthy subjects who received up to three times the recommended dose, peak estazolam plasma concentrations occurred within two hours after dosing (range 0.5 to 6.0 hours) and were proportional to the administered dose, suggesting linear pharmacokinetics over the dosage range tested.

Estazolam is extensively metabolized. The elimination of the parent drug takes place via hepatic metabolism of estazolam to hydroxylated and other metabolites that are eliminated largely in the urine both free and conjugated. Less than 5% of a 2 mg dose of estazolam was excreted unchanged in the urine, with only 4% of the dose appearing in the feces. Radiolabel mass balance studies indicate that the main route of excretion is via the kidneys. After 5 days, 87% of the administered radioactivity was excreted in human urine. Less than 4% of the dose was excreted unchanged.

Tissue LocationsKidney
Cellular LocationsMembrane

Uses & manufacturing

UsesFor the short-term management of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings.
Use ClassificationPharmaceuticals
Applications · 2 items

DescriptionEstazolam, sold under the brand name Prosom among others, is a tranquilizer medication of the triazolobenzodiazepine (TBZD) class, which are benzodiazepines (BZDs) fused with a triazole ring . It possesses anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant properties.

UsesA benzodiazepine derivative possessing anxiolytic, anticonvulsant, and muscle relaxant properties. It is commonly prescribed to treat short-term insomnia. Controlled Substance.

Upstream & downstream products

Upstream raw materials

4-ChloronitrobenzenephenylacetonitrileTriethyl orthoformateChloroacetyl chlorideHexamethylenetetramineFormylhydrazine2-(2-Acetylhydrazino)-7-chloro-5-phenyl-3H-1,4-benzodiazepineN-desmethyl-N(4)-desoxychlordiazepoxideFormamidine hydrochloride
Additional notes · 1 item

DefinitionChEBI: A triazolo[4,3-a][1,4]benzodiazepine having a phenyl group at position 6 and a chloro substituent at position 8. A short-acting benzodiazepine with general properties similar to diazepam, it is given by mouth as a hypnotic in the short-term ma agement of insomnia.